Related Experiment Videos
The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives
S Hegewisch-Becker1, D K Hossfeld
1Department of Oncology and Hematology, University Medical Clinic Eppendorf, Hamburg, Germany.
Annals of Hematology
|March 1, 1996
Summary
Multidrug resistance (MDR) in blood cancers often causes treatment failure. Research shows P-glycoprotein expression correlates with chemotherapy response, but standardized detection methods are needed to confirm findings.
Area of Science:
- Hematologic Malignancies
- Cancer Biology
- Pharmacology
Background:
- The multidrug resistant (MDR) phenotype is a significant factor in treatment failure for hematologic malignancies.
- P-glycoprotein, the MDR1 gene product, is frequently studied in leukemia, lymphoma, and myeloma.
- Existing studies show a correlation between P-glycoprotein expression and chemotherapy response in myelogenous leukemia and myeloma, but results vary.
Purpose of the Study:
- To review current clinical data on MDR in hematologic malignancies.
- To provide guidelines for future clinical trials targeting MDR reversal.
- To discuss the potential of idarubicin in overcoming the MDR phenotype.
Main Methods:
- Review of existing clinical data on P-glycoprotein expression and MDR modulators.
- Analysis of studies investigating the correlation between P-glycoprotein and chemotherapy response.
- Evaluation of clinical results from trials using MDR modulators.
Main Results:
- P-glycoprotein expression is linked to chemotherapy response in certain blood cancers, though detection discrepancies exist.
- Standardized detection methods are crucial for definitive conclusions.
- Clinical trials using MDR modulators with chemotherapy have shown encouraging results.
Conclusions:
- MDR is a key challenge in treating hematologic malignancies.
- Further research with standardized methods is needed to fully understand and overcome P-glycoprotein-mediated resistance.
- MDR modulators and agents like idarubicin show promise in reversing the MDR phenotype.